Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Heron Therapeutics Inc (NASDAQ: HRTX) closed at $2.59 down -1.89% from its previous closing price of $2.64. In other words, the price has decreased by $-1.89 from its previous closing price. On the day, 2.09 million shares were traded. HRTX stock price reached its highest trading level at $2.71 during the session, while it also had its lowest trading level at $2.58.
Ratios:
For a deeper understanding of Heron Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 2.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 13, 2024, Reiterated its Buy rating but revised its target price to $5 from $4 previously.
On May 27, 2020, Guggenheim started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on February 20, 2020, while the target price for the stock was revised from $50 to $48.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’23 when Forbes William P bought 25,000 shares for $1.09 per share. The transaction valued at 27,250 led to the insider holds 79,000 shares of the business.
Collard Craig A bought 150,000 shares of HRTX for $137,970 on Nov 16 ’23. The Chief Executive Officer now owns 186,496 shares after completing the transaction at $0.92 per share. On Nov 16 ’23, another insider, Duarte Ira, who serves as the EVP, Chief Financial Officer of the company, bought 85,000 shares for $0.89 each. As a result, the insider paid 75,599 and bolstered with 85,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 389352064 and an Enterprise Value of 496086464. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06. Its current Enterprise Value per Revenue stands at 3.905 whereas that against EBITDA is -5.505.
Stock Price History:
The Beta on a monthly basis for HRTX is 1.68, which has changed by -0.0075187683 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, HRTX has reached a high of $3.22, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -5.25%, while the 200-Day Moving Average is calculated to be 47.48%.
Shares Statistics:
For the past three months, HRTX has traded an average of 2.61M shares per day and 1689850 over the past ten days. A total of 150.29M shares are outstanding, with a floating share count of 142.69M. Insiders hold about 5.08% of the company’s shares, while institutions hold 71.10% stake in the company. Shares short for HRTX as of 1711584000 were 25551664 with a Short Ratio of 9.80, compared to 1709164800 on 24532587. Therefore, it implies a Short% of Shares Outstanding of 25551664 and a Short% of Float of 19.569999.
Earnings Estimates
Currently, RTX Corporation analysts are dedicated to thoroughly evaluating and rating the performance of Heron Therapeutics Inc (HRTX) in the stock market.The consensus estimate for the next quarter is $399.92, with high estimates of $2.59 and low estimates of $26.89.
